BlueRock accelerates Parkinson’s disease therapy to Phase III

US-based Bayer subsidiary BlueRock Therapeutics has accelerated bemdaneprocel, its investigational cell therapy candidate for Parkinson’s disease, to Phase III trials after a Phase I study saw the treatment was well tolerated.